Novavax reported $2.17B in Current Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adamas Pharmaceuticals ADMS:US 108M 7.65M
Adma Biologics ADMA:US $ 174.78M 3.43M
AstraZeneca AZN:LN 26.69B 583M
Astrazeneca AZN:US 26.69B 583M
Dynavax Technologies DVAX:US $ 852.67M 268.76M
Genocea Biosciences GNCA:US $ 50.61M 12.3M
Geron GERN:US $ 179.36M 22.41M
GlaxoSmithKline GSK:LN 18.25B 688M
Kindred Biosciences KIN:US 79.08M 8K
Mannkind MNKD:US $ 159.21M 20.7M
Minerva Neurosciences NERV:US $ 67.44M 7.79M
Moderna Inc MRNA:US 13.42B 2.46B
Novartis NVS:US $ 26253M 2445M
Novavax NVAX:US $ 2174.18M 180.81M
Pain Therapeutics PTIE:US $ 251.92M 27.64M
Peregrine Pharmaceuticals PPHM:US $ 206.92M 6.14M
Sarepta Therapeutics SRPT:US $ 2185.31M 79.91M